BioMap Advances Toward Hong Kong IPO with Confidential Filing, Powered by 268B-Parameter Life Science AI Platform
BioMap
Developer of Innovative Drug R&D Platform
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
▲August 1-22025 Biomedical Innovation ExpoScan to register
Note:This article does not constitute any investment opinions or recommendations., subject to official/company announcements;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprint requires authorization.
Reported by Bloomberg,BioMapBioMapCEOLiu Wei said that the company plans to seek a public listing in Hong Kong within the next one and a half years, as Hong Kong is likeBioMapThe preferred listing destination for technology companies in the early stages of entrepreneurship.
BioMapAs a pioneer in global life science foundational large models, BioMap decodes the underlying rules of genomes, proteins, cells, and biological systems through a 210 billion-parameter cross-modal biolinguistic large model, building high-quality AI task models for life sciences with less data and cost consumption.
Currently,BioMapAchieved State-of-the-Art performance in over 200 task models in the fields of drug research and development, biomanufacturing, and healthcare, serving more than 300 global users, with total customer orders exceeding 2 billion US dollars. Empowered users to achieve numerous breakthrough results in AI-driven novel protein design, AI target discovery, and AI enzyme design.
BioMapFounded by the founder of BaiduRobin Li, co-founded by former Baidu Ventures CEO Liu Wei, with a core team composed of senior industry executives such as the former global vice president of Novo Nordisk and the former global vice president of SAP. Research and development centers have been established in Silicon Valley, Beijing, Suzhou, and Hong Kong, securing over 200 million US dollars in venture capital.
Copyright statement: This article is reproduced fromRyan Capital,Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
Rooted in Shanghai and radiating globally, PharmaCircle, as a biopharmaceutical industry-level strategic platform, is on a mission to "enable the borderless flow of intelligence and connections." It has built an empowering system that covers the entire pharmaceutical industry chain, including drug research and development, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource linking, industrial think tanks, and ecosystem communities—it is creating the infrastructure for the flow of pharmaceutical value in China.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises' leapfrog growth.